Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06990763

Network Pharmacology Was Applied to Explore the Mechanism of Remimazolam Applied in General Anesthesia for Gynecological Surgeries

Clinical and Molecular Mechanism Study of Remimazolam Regulating the N/OFQ-inflammation-immune Axis to Optimize the Effect of General Anesthesia in Gynecological Surgery

Status
Not Yet Recruiting
Phase
N/A
Study type
Interventional
Enrollment
40 (estimated)
Sponsor
Second Hospital of Shanxi Medical University · Academic / Other
Sex
Female
Age
18 Years – 64 Years
Healthy volunteers
Not accepted

Summary

To explore the related mechanisms by which remimazolam regulates hemodynamic stability, inflammatory factors and the immune system in patients undergoing general anesthesia for gynecological surgeries.

Detailed description

①Clinical effect evaluation of remimazolam 1. Compare the hemodynamic stability (heart rate, mean arterial pressure, blood oxygen saturation), anesthesia efficiency (induction time, recovery time), and safety (incidence of adverse reactions such as hypotension, hypoxemia, and injection pain) of remimazolam alone, propofol alone, and their combination in general anesthesia for gynecological surgeries. 2. Clarify the optimal dose range of remimazolam and its synergistic effect with propofol, and optimize the anesthetic medication regimen. * The regulatory effect of remimazolam on the inflammation-immune axis and oxidative stress Detect the dynamic changes of serum inflammatory factors (IL-6, IL-10, TNF-α), immune indicators (CD3+, CD4+, CD4+/CD8+) and oxidative stress markers (SOD, MDA) of patients before and after the operation, and analyze the regulatory effect of remimazolam on the above indicators.

Conditions

Interventions

TypeNameDescription
DRUGRemimazolamRemimazolam, sufentanil and rocuronium were used during induction, and remimazolam and refentanil were used during maintenance
DRUGpropofolPropofol, sufentanil and rocuronium were used during induction, and propofol and remifentanil were used during maintenance

Timeline

Start date
2025-06-01
Primary completion
2025-12-01
Completion
2026-01-01
First posted
2025-05-25
Last updated
2025-05-25

Source: ClinicalTrials.gov record NCT06990763. Inclusion in this directory is not an endorsement.